Abstract
Chronic inflammation is involved in the development of autoimmune and neuropsychiatric diseases, which reduce quality of life. We have discovered a “gateway reflex”, in which activation of specific neural circuits via environmental factors such as stress induces microinflammation in local vascular regions, and promotes the formation of tissue entry points for pathogenic immune cells via increased vascular permeability. Currently, in the AMED Moonshot Research and Development Project, we are working on the development of technology for ultra‐early detection of “buds of disease” from the unaffected state, using as indicators the extremely small amounts of biomarkers that are expressed in a microinflammation‐dependent manner. To achieve this goal, the project aims to develop quantum measurement and imaging technologies, which enable ultra‐sensitive and ultra‐precise detection of such markers from biological samples, as well as a platform for integrated analysis of genetic, physiological, and behavioral information using artificial intelligence (AI) . In this review, we outlines our recently identified potential diagnostic markers of neuropsychiatric disorders and the development of quantum technologies, which contribute to preventive diagnosis using such biomarkers.
